Last reviewed · How we verify
Multi-virus Specific T cells
At a glance
| Generic name | Multi-virus Specific T cells |
|---|---|
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT (PHASE1)
- In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies (PHASE1)
- Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC (PHASE2)
- Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant (PHASE1, PHASE2)
- Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant (PHASE2, PHASE3)
- Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT (PHASE1, PHASE2)
- A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multi-virus Specific T cells CI brief — competitive landscape report
- Multi-virus Specific T cells updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI